Loading
Urologist who set the definitions for BCG-unresponsive bladder cancer and leads the International Bladder Cancer Group.
Ashish Kamat led the consensus that defined BCG-unresponsive non-muscle-invasive bladder cancer and the trial endpoints now used by regulators, and has led studies of BCG dosing, intravesical therapy and urinary biomarkers. He is president of the International Bladder Cancer Group and a senior author of the Lancet seminar on bladder cancer. His work shapes the entire non-muscle-invasive trial landscape.
Shares Bladder & urothelial cancer and the tags urothelial, surgery.
Shares Bladder & urothelial cancer and the tag urothelial.
Shares MD Anderson Cancer Center and the tag surgery.
Shares MD Anderson Cancer Center and the tag surgery.
Shares Bladder & urothelial cancer and the tag urothelial.
Shares Bladder & urothelial cancer and the tag urothelial.
Shares Bladder & urothelial cancer and the tag urothelial.
Shares MD Anderson Cancer Center, Bladder & urothelial cancer.